- Different active compounds: Amanita = muscimol + ibotenic acid (GABA-A agonist + glutamate analog). Psilocybin = psilocin (5-HT2A agonist).
- Different experience: Amanita is more dissociative, dreamlike, sedative, with autonomic effects. Psilocybin is more visual, emotional, mystical-type, with introspective lift.
- Different research base: Psilocybin has Phase 2/3 trials for depression, PTSD, addiction. Amanita has essentially no clinical trial evidence.
- Different legality: Psilocybin is Schedule I in most countries. Amanita is unscheduled in the US and many countries (legal grey area).
- Amanita’s appeal is mostly its legality. The “legal psychedelic” framing oversimplifies; it has its own dose-response and toxicity profile.
Side-by-side comparison
| Dimension | Amanita Muscaria | Psilocybin Mushrooms |
|---|---|---|
| Active compounds | Muscimol (GABA-A agonist), Ibotenic acid (NMDA agonist, neurotoxic when not converted) | Psilocybin → psilocin (5-HT2A partial agonist) |
| Receptor target | GABA-A primarily; glutamate (NMDA) for ibotenic | Serotonin 5-HT2A primarily |
| Subjective experience | Dissociative, dreamlike, sedative; less visual; bodily heaviness | Visual, emotional, mystical-type; cognitive flexibility |
| Onset / duration | 30-120 min onset; 6-10 hour duration; long sleep often follows | 20-40 min onset; 4-6 hour duration |
| Bodily effects | Salivation, sweating, muscle twitches, nausea, occasional confusion | Mild nausea early, then lighter; pupils dilated; raised BP/HR |
| Clinical research | Essentially none | Phase 2/3 for depression, PTSD, addiction |
| Microdosing literature | Self-report only; growing community | Survey + small placebo-controlled trials |
| Legality (US, May 2026) | Unscheduled in most states (legal grey area) | Schedule I federal; Oregon and Colorado regulated |
| Toxicity concerns | Ibotenic acid is neurotoxic; preparation matters; risk of misidentification with truly toxic Amanita species (A. phalloides — fatal) | No documented lethal overdose at recreational/therapeutic doses; misidentification risk lower |
| Best for | Sleep, dreamlike states, certain shamanic traditions | Therapeutic depression/PTSD work, mystical experience, microdosing |
Amanita muscaria, in plain terms
Amanita muscaria is the iconic red-with-white-dots mushroom of fairy tales. It contains muscimol (the primary psychoactive, a GABA-A agonist) and ibotenic acid (a neurotoxic glutamate analog that partially decarboxylates to muscimol with proper preparation).
Traditional preparation includes drying or boiling, which converts ibotenic acid to muscimol and reduces toxicity. Sourcing matters: a cap that has been air-dried for months has a different muscimol-to-ibotenic ratio than a fresh one.
The experience is more dissociative than psychedelic in the classical sense. Users describe a shift toward dreamlike states, lucid-feeling sleep, body heaviness, and reduced anxiety. Visual hallucinations are less common than with psilocybin.
Psilocybin mushrooms, in plain terms
Psilocybe genus mushrooms (cubensis, semilanceata, azurescens, others) contain psilocybin, which is dephosphorylated in the body to psilocin. Psilocin is a partial agonist at 5-HT2A serotonin receptors, the receptor responsible for the classical psychedelic experience.
Phase 2/3 trials at COMPASS, JHU, Imperial, and elsewhere have established psilocybin as the most-studied classical psychedelic for depression, PTSD, addiction, and cluster headache. The experience is visual, introspective, often described as emotionally cathartic or mystical.
When each fits
Amanita muscaria fits when
- You want a sedating, dreamlike state, not classical psychedelia.
- You are exploring shamanic traditions where Amanita has historic use (Siberian, some indigenous European).
- You are in a region where psilocybin is illegal but Amanita is unscheduled.
- You are interested in sleep-adjacent introspection.
Caveats: research base is essentially absent; preparation matters; misidentification risk with truly toxic Amanita species is real.
Psilocybin fits when
- You want classical psychedelic effects (visual, introspective, mystical).
- You are interested in evidence-based therapeutic protocols (depression, PTSD, addiction).
- Your region permits supervised use (Oregon, Colorado, research trials, compassionate access).
- You are microdosing for mood/focus and want the most-studied compound.
Caveats: Schedule I in most jurisdictions; sourcing risk in unregulated markets.
Risks specific to each
Amanita-specific risks
- Ibotenic acid toxicity. Insufficient preparation (raw/wet) leaves more ibotenic acid intact. At higher doses, ibotenic acid causes confusion, vomiting, occasional seizure-like activity. Proper drying or simmering reduces but does not eliminate.
- Misidentification. A. muscaria is visually distinctive but other Amanita species (A. phalloides, the death cap) are deadly. Foragers have died from misidentification.
- Autonomic effects. Salivation, sweating, vomiting common. Cholinergic toxicity from related Amanita species can be confused with muscarine effects.
- No reversal protocol. Unlike opioid overdose with naloxone, no specific antidote exists for Amanita overdose. Supportive care only.
Psilocybin-specific risks
- Acute psychological reactions. Bad trips, anxiety, paranoia. Largely set/setting dependent.
- Cardiovascular load. BP and HR elevation. Pre-existing CV disease is a contraindication.
- Drug interactions. Lithium (contraindicated), MAOIs (dangerous), SSRIs (blunted experience). See our interactions sub-hub.
- HPPD. Hallucinogen-persisting perception disorder is rare but documented.
Should you combine them?
No documented research on Amanita + psilocybin combinations. Mechanism logic: GABA-A agonism (sedating) opposing 5-HT2A agonism (activating). Some users report Amanita “softens” psilocybin trips. The combination is not characterized in the literature; assume unknown risk.
